Because symptoms are similar to those of gastroesophageal reflux disease, achalasia is often misdiagnosed, explained Eric Low, MD, MPH, gastroenterology fellow at University of California, San Diego at Digestive Disease Week 2022.
Eric Low, MD, MPH, gastroenterology fellow at University of California, San Diego, explained the clinical manifestation of ahcalsia and the challenges of diagnosing the rare condition at Digestive Disease Week 2022.
Transcript
Can you explain what achalasia is, and how it manifests clinically?
Achalasia, it's a rare esophageal motility disorder. It's characterized by impaired relaxation of the lower esophageal sphincter, so it's the sphincter that connects the esophagus to the stomach. Normally, during swallowing, when you initiate a swallow, the lower esophageal sphincter will open up and allow food to go from the esophagus into the stomach. A normal transition.
Another characteristic feature of achalasia is ineffective esophageal peristalsis. Patients with achalasia don't have the ability to normally move food down the esophagus like in normal physiology. Individuals with a achalasia unfortunately have a double whammy against normal swallowing. They can't move the food in the right direction, and then they also have to push against a tight sphincter down to the bottom of the esophagus that is hard to push against. As you can imagine, individuals and achalasia have typically dysphasia for both solids and liquids. Other common symptoms of achalasia include regurgitation, heartburn, noncardiac chest pain, and weight loss.
As a rare disorder, is there a delay in diagnosis for achalasia? What are the challenges around misdiagnosis?
Achalasia is a rare disease in general. The incidence is about 1 in 100,000 persons per year, and then the prevalence is about 10 per 100,000 persons per year. It is often misdiagnosed because there's so much overlap in symptoms with gastroesophageal reflux disease (GERD), which is very, very prevalent and has a very high incidence in the US.
There's a recent study that showed about greater than 80 million people will experience symptoms of GERD, so sometimes achalasia patients are misdiagnosed as having gastroesophageal reflux disease or GERD because of the overlap in symptoms such as heartburn, regurgitation. In order to bridge this gap and reduce the amount of time that patients spend with the symptoms or amount of time being undiagnosed with achalasia, typically patients will undergo an upper endoscopy procedure. That can often be normal, so the esophagus can look normal, and patients, again, are still misdiagnosed as having gastroesophageal reflux disease. So it is important, if they still continue to have symptoms despite being on PPI [proton-pump inhibitor] therapy, that they undergo additional evaluation with either a barium esophagram or high resolution esophageal manometry in order to diagnose their dysphasia issue.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More